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Abstract
The main clinical features of nephrotic syndrome (NS) are heavy proteinuria, hypoalbuminemia, hyperlipidemia and edema.
In addition, multiple abnormalities in the coagulation pathway may be a consequence of the NS. Both arterial and venous
thromboembolic complications (TEC) are relatively common and serious consequences of NS. In addition, arterial and
venous thrombosis might be unexpected events during an exacerbation of NS. Embolic episodes may manifest in different
regions of the body such as the brain or the lung. Hence, predisposing factors, personal and family history of TEC, thrombosis
location and evolution should be always investigated in children with NS.
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Introduction
Venous and arterial thromboembolic complications
(TEC) are relatively infrequent during infancy and
childhood but still cause significant morbidity [1,2].
Several conditions such as cancer, chemotherapy,
cardiac diseases, central venous lines, surgery, infec-
tions, trauma, congenital thrombophilia and nephro-
tic syndrome (NS) may predispose children to TEC.
Additionally, in several cases these risk factors may
interact with each other and enhance the likelihood of
developing thrombotic episodes. Conditions that
predispose patients to TEC (e.g. NS, inflammatory
bowel disease, diabetes, obesity, etc.) may themselves
induce thrombosis by contributing to its clinical onset
in patients with true thrombophilic states [3].
Heavy proteinuria, due to an abnormal increase in
glomerular permeability, is associated with NS.
Proteinuria occurs in association with primary or
secondary glomerular disorder, and combined forms
of glomerulonephritis. The main clinical features of
NS are heavy proteinuria, hypoalbuminemia, hyper-
lipidemia and edema. Coagulopathy and disturbances
in haemostasis leading to a high risk of TEC have been
reported in NS [4]. Massive proteinuria and severe
hypoalbuminemia have predictive value for high
thrombotic risk [5]. Therefore, a lower incidence of
TEC has been showed in children compared to adults
with NS [6]. Autopsy analysis has shown that 38% of
children with renal vein thrombosis were associated
with NS [7]. Subclinical pulmonary embolism was
found in 28% of children with NS by scintigraphic
pulmonary ventilation and perfusion studies [8]. This
incidence appears to be fairly high. Therefore,
recommendations and frequency of the investigations
in children during the acute episodes of NS should be
accomplished.
The present review critically accesses the available
information about this relatively infrequent but
serious complication of NS during childhood.
ISSN 1024-5332 print/ISSN 1607-8454 online q 2007 Informa UK Ltd.
DOI: 10.1080/10245330600940048
Correspondence: M. Zaffanello, Department of Pediatrics, University of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.
Tel: þ 39 45 807 4385. Fax: þ 39 45 820 0993. E-mail: marco.zaffanello@univr.it
†E-mail: massimo.franchini@azosp.vr.it
Hematology, February 2007; 12(1): 69–73
Pathogenesis
Multiple abnormalities in the coagulation pathway are
observed in NS. The hypercoagulable states and the
TEC in NS are attributable to a loss of intermediate-
size antithrombotic proteins (ATIII) in the urine as a
direct result of heavy proteinuria. However, there is a
increase in the pro-coagulant serum proteins (factors
I, II, V, VII, VIII, X, and XIII) due to their increased
hepatic synthesis [9]. A significant increase in protein
C activity in NS patients represents a protective
mechanism against thrombosis. The fibrinolytic
system also plays an important role in preventing
thrombosis in these patients [10]. In addition,
congenital abnormalities of coagulation factors and
NS may simultaneously be associated [11]. Hyper-
coagulable states can be classified as acquired, for
example, if they arise as a consequence of the heavy
proteinuria, or inherited, if only causally associated to
NS. The acquired and inherited conditions leading to
predisposition to TEC in childhood NS are shown in
Table I.
Acquired thrombophilia
Several studies have focused on the abnormalities of
the coagulation pathways in NS patients. The TEC in
NS have been attributed to low plasma ATIII levels.
Plasma ATIII levels have been shown to correlate with
albumin levels and degree of proteinuria in NS [12].
However, the excess thrombin generation played a
part in the development of the acquired deficiency of
ATIII in NS [8].
A reduction of ATIII in NS may also be associated
with low free serum protein S levels. Peripheral arterial
thrombosis was reported in a child with longstanding
NS with low acquired serum ATIII and protein S
levels [13]. Acquired ATIII and protein S deficiency
appeared to be one of the many risk factors for TEC in
children with NS [14]. Therefore, TEC could be due
to combined low plasma ATIII, protein S and protein
C deficiency, albumin, high fibrinogen and cholesterol
levels [5]. The levels of protein S, protein C and ATIII
are frequently decreased in NS because of their loss in
the urine [8]. Furthermore, anticoagulant proteins S
and protein C in the serum may also remain
functionally inactive because of an increase in the
hepatic synthesis of binding proteins for protein S and
protein C [15].
TEC may result from an increase of both the plasma
fibrinogen levels and platelet counts. Abnormal fibrin
network conformation may be involved in
hypofibrinolysis. Therefore, albumin supplementation
partially restores normal fibrin architecture and
increases the rate of fibrinolysis [16]. However,
platelets are dysfunctional and often increased in
number in NS. Increased activation of blood platelets
may be an independent risk factor of TEC in the early
stages of the NS relapse. Increased platelet hyperag-
gregability may be due to increased platelet synthesis
of thromboxane in response to the hypoalbuminemia
[17,18].
An important cause of thrombosis in NS, that
should be always borne in mind, is volume depletion,
especially iatrogenic through over vigorous diuresis
[19]. The risk of TEC in NS is increased by
hyperviscosity of the blood caused by hyperfibrino-
genemia, and intravascular volume depletion resulting
from the inappropriate use of diuretics [20,21].
Inherited thrombophilia
Genetic prothrombotic defects in protein C, protein S
and ATIII deficiency, mutations of coagulation factors II
andV, elevated lipoprotein (a) areestablished risk factors
for TEC [22]. The acquired hypercoagulability in NS
may coincide with an underlying inherited thrombophi-
lia. Furthermore, TEC may be associated with ATIII
deficiency, increased concentrations of fibrinogen,
factors V and VIII, and platelet hyperaggregability
Table I. Acquired and inherited thrombophilia in children with NS.
Acquired thrombophilia Conditions Pathophysiology
ATIII Serum reduction Urinary loss
Protein S Serum reduction Urinary loss
Protein S Raised activity Increased hepatic synthesis
Protein C Raised activity Increased hepatic synthesis
Fibrin network Hypofibrinolysis Abnormal conformation
Proteins S and C levels Serum reduction Increased binding proteins
Platelets Dysfunctional, Increased activation Increased number, increased synthesis of thromboxane
tPA, PAI-1 Increased concentration Cyclosporine A
Inherited thrombophilia
Protein C, protein S, ATIII Defect
Lipoprotein (a) Raised
Coagulation factors V and II Gene mutations
Factor V Leiden Presence
Prothrombin variant (20210G! A) Presence
MTHFR gene Gene mutation
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[23]. The prevalence of the factor V mutation Arg506!
Gln (factor V Leiden), prothrombin variant
(20210G! A), and homozygosity of Ala677! Val in
the methylenetetrahydrofolate reductase gene
(MTHFR) in children with NS were assessed. Although
TEC occurred in 11% of the children with NS, none of
the known inherited risk factors has been identified [23].
These data support the hypotheses that there is a low
incidence of inherited thombogenic factors in NS
patients with thrombosis. Likewise a child with steroid-
dependent NS and a homozygous mutation of MTHFR
genedeveloped thrombosis in superior mesentericartery
[24] has been reported. In addition, a young male with
concomitant deep vein thrombosis, idiopathic NS and
resistance toactivated protein C, the factor V Leiden was
found to increase the risk of thrombosis [25]. Martinez
and co-workers investigated the presence of genetic
prothrombotic factors of patients with glomerulone-
phritiswith or without a historyof TECand/or NS.They
found an increased prevalence of heterozygous factor V
Leiden in patients with a history of thrombotic events.
These patients at risk of thrombosis may benefit from
TEC prophylaxis [26].
Clinical features
The incidence of TEC in children may be linked to
pronounced hypoalbuminemia and proteinuria [27].
The incidence of TEC in children with severe NS is
high (1.8–5%), but frequently underestimated [22].
TEC (arterial or venous thrombosis, pulmonary
embolism) were reported in 5.4% of children with
NS [28].
Arterial and venous thrombosis may be an
unexpected event during exacerbation of the NS.
Children with membranous nephropathy may have a
higher than previously recognised risk of TEC [29].
Embolic episodes may manifest in different regions of
the body, such as the brain or the lung. Deep venous
thrombosis and pulmonary embolism were found to
be secondary to the acquired protein S deficiency in a
paediatric case of the NS [30]. Two patients with NS
developed venous thromboses without the presence of
predisposing factors or coagulation abnormalities
[29].
An uncommon, but known complication of NS is
pulmonary thrombosis. Pulmonary embolism can lead
to persistent tachypnea in childhood NS [31]. There-
fore, pulmonary thrombosis may present with subtle
symptoms and requires prompt diagnosis and treat-
ment to prevent fatal outcomes [32]. Physicians
should be alert to the possible complications of
pulmonary embolism when treating the clinical
symptoms of NS patients. The occurrence of
thrombotic events is not always correlated with the
clinical or laboratory severity of the NS, except for the
association with elevated levels of fibrinogen and
ATIII. Serial ventilation/perfusion lung scans may
provide valuable clues during evaluation of these
patients [33].
Cerebral venous thrombosis is a rare complication
of NS. Appenzeller and co-workers showed that the
aetiology of the cerebral venous thrombosis could be
determined in 88% of the patients of all ages (from
childhood to adulthood) but only in 4% of the patients
with NS [34]. The possible presenting symptoms may
include headaches and facial palsies remitting with
heparin therapy [35]. Subtle symptoms may be
alerting manifestations. A young boy with NS,
presented with dehydration, and vague neurological
symptoms with decreased serum ATIII levels. Sub-
sequently, he developed seizures and cerebral sino-
venous thrombosis [36]. Magnetic resonance imaging
with venography was important in the early diagnosis
of the cerebral sinus thrombosis. Anticoagulation
therapy has been shown to be effective in improving
the neurological outcome in children with NS [37].
Acute subclavian and brachial artery thrombosis are
rare complications of NS [38]. Siddiqui and co-
workers reported sustained acute thrombosis of the
arterial bypass grafts in two patients with NS [39].
TEC are generally venous, whereas arterial thrombo-
sis occurred less frequently. Hypercoagulability
caused by acquired NS is not considered a frequent
cause of acute thrombosis of the arterial bypass grafts
[39].
Weisz and co-workers reported an asymptomatic
intracardiac thrombus in a child with frequently
relapsing steroid-sensitive NS and a ventricular septal
defect [40]. Persistent hyperlipidemia in membranous
nephropathy may increase the risk of cardiovascular
diseases [41]. Furthermore, acute myocardial infarc-
tion, probably due to arterial thrombosis attributable
to a hypercoagulable state resulting from the NS, was
observed in a young adult [42].
Laboratory investigation
Predisposing factors, personal and family history of
TEC, thrombosis location and the evolution of the
disease should be always investigated in children with
NS. Potential underlying prothrombotic conditions in
childhood include acquiredantiphospholipidantibodies
or the lupus anticoagulant and hyperhomocysteinemia,
abnormalities of the inherited anticoagulant factors
including protein C, protein S, ATIII and factor V
Leiden. Other abnormalities may result in increased
lipoprotein (a) and hyperprothrombinemia due to
prothrombin G20210A mutation [43,44].
Treatment
The therapeutic approach to thrombosis in children is
with anticoagulants (low molecular weight heparin)
and/or with fibrinolytic agents (streptokinase, uro-
kinase, tissue plasminogen activator (tPA)) [26]. High
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dosage heparinization may be necessary in children
with deep vein thrombosis. Budd–Chiari syndrome
resolved after immediate heparin infusion in a very
young boy with NS due to hepatic vein and inferior
vena cava thrombosis [45]. Satisfactory thrombolysis
of an arterial leg thrombosis after 4 days of continuous
catheter-directed low-dose alteplase was achieved in a
patient with relapsing NS [46]. Therefore, the most
widely used thrombolytic agent used from many years
is tPA [47,48]. TPA treatment in children was first
reported in 1990 [49]. TPA has shown efficacy in
thrombolysis in paediatric patient and was not
contraindicated in cases of NS [50]. However, no
studies assessing its efficacy and safety in children is
available [51].
The correction of diminished ATIII levels, by
substitution of ATIII concentrates, is beneficial in
cases in which is necessary to interrupt an enhanced
coagulation process [52]. Theoretically, low-dose
aspirin therapy should compensate for the low ATIII
levels, although controlled trials of aspirin therapy in
NS have not been performed [24].
Pulmonary embolism should be considered in
children with tachypnea, especially when other venous
thromboembolic risk factors are present, to avoid
delay in anticoagulant treatment and a potentially fatal
outcome [37]. Pulmonary thrombosis in two tachyp-
neic young girls, presenting with severe oedema in NS
relapse, was diagnosed with CT pulmonary angio-
graphy. They were treated with continuous heparin
infusion with resolution of the pulmonary thrombo-
embolism [36]. The mortality rate in NS patients with
lung TEC may increase if treatment is delayed. The
importance of lung perfusion scan, performing
thrombolytic therapy (streptokinase, heparin and
warfarin) and follow-up therapy should be empha-
sized [52].
To ensure optimal outcome in cerebral sinovenous
thrombosis the essential measures are anticoagulant
therapy with heparin and fresh frozen plasma for
correcting the ATIII levels [40]. Thrombosis of the
superior sagittal and straight sinus, leading to thalamic
stoke, were successfully treated with subcutaneous
low-molecular-weight heparin and warfarin in children
with steroid-resistant NS [41,53,54].
Conclusions
The risk of TEC in patients with NS should not be
underestimated. Although rare, the TEC are among
the most-serious life-threatening complications in
children with NS. TEC occur less commonly in
paediatric than the adult patients. The most com-
monly involved vessels in vascular thrombosis are the
deep veins of the legs, the inferior vena cava, renal
veins, superior vena cava, the mesenteric artery,
hepatic veins and the middle cerebral arteries.
Iatrogenic thrombotic risk factors (diuretics, dehy-
dration, and infections) should be avoided, whereas
inherited risk factors should be investigated. Adequate
therapy with anticoagulants and fibrinolytic drugs
should be recommended in children with acute
symptoms, inasmuch as prophylaxis is necessary in
relapsing patients.
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